Prophylix AS has entered a manufacturing collaboration with Emergent BioSolutions Inc. (NYSE:EBS) whereby Emergent will manufacture Prophylix’s developmental drug NAITgam [Human Platelet Antigen 1a Immunoglobulin (anti-HPA-1a)]. The collaboration will leverage Emergent’s proven platform for manufacturing of plasma-derived hyperimmune drug products to enable the development of the first drug for the prevention of the rare but potentially chronically disabling or life-threatening pediatric condition fetal-neonatal alloimmune thrombocytopenia (FNAIT). Today, no drug is approved for the prevention or treatment of FNAIT.

Read more